Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI).

Rogiers A, Tondini C, Grimes JM, Trager MH, Nahm S, Zubiri L, Papneja N, Elkrief A, Borgers J, Rose A, Mangana J, Erdmann M, Da Silva IP, Posch C, Hauschild A, Zimmer L, Queirolo P, Robert C, Suijkerbuijk K, Ascierto PA, Lorigan P, Carvajal R, Rahma OE, Mandala M, Long GV (2020)

Publication Type: Conference contribution

Publication year: 2020

Journal

Publisher: AMER ASSOC CANCER RESEARCH

City/Town: PHILADELPHIA

Conference Proceedings Title: CLINICAL CANCER RESEARCH

DOI: 10.1158/1557-3265.covid-19-s02-01

Additional Organisation(s)

Involved external institutions

Columbia University United States (USA) (US) Melanoma Institute Australia Australia (AU) Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" Italy (IT) Dana–Farber Cancer Institute United States (USA) (US) Christie NHS Foundation Trust United Kingdom (GB) Azienda Ospedaliera Papa Giovanni XXIII Italy (IT) European Institute of Oncology / Istituto Europeo di Oncologia (IEO) Italy (IT) University of Toronto Canada (CA) Hôpital général juif - Jewish General Hospital Canada (CA) Netherlands Cancer Institute (NKI) Netherlands (NL) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Universitätsspital Zürich (USZ) Switzerland (CH) Technische Universität München (TUM) Germany (DE) Massachusetts General Hospital United States (USA) (US) Universitätsklinikum Essen Germany (DE) Institut Gustave-Roussy France (FR) Westmead Hospital Australia (AU) University Medical Centre Utrecht (UMC Utrecht) Netherlands (NL)

How to cite

APA:

Rogiers, A., Tondini, C., Grimes, J.M., Trager, M.H., Nahm, S., Zubiri, L.,... Long, G.V. (2020). Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI). In CLINICAL CANCER RESEARCH. PHILADELPHIA: AMER ASSOC CANCER RESEARCH.

MLA:

Rogiers, Aljosja, et al. "Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)." Proceedings of the Annual Meeting of the American-Association-for-Cancer-Research (AACR) PHILADELPHIA: AMER ASSOC CANCER RESEARCH, 2020.

BibTeX: Download